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Abstract
Background: Natural killer (NK) cells are an important resource of the innate immune system directly involved in
the spontaneous recognition and lysis of virus-infected and tumor cells. An exquisite balance of inhibitory and
activating receptors tightly controls the NK cell activity. At present, one of the best-characterized activating
receptors is NKG2D, which promotes the NK-mediated lysis of target cells by binding to a family of cell surface
ligands encoded by the MHC class I chain-related (MIC) genes, among others. The goal of this study was to
describe the expression pattern of MICA and MICB at the molecular and cellular levels in human cervical cancer
cell lines infected or not with human papillomavirus, as well as in a non-tumorigenic keratinocyte cell line.
Results: Here we show that MICA and MICB exhibit differential expression patterns among HPV-infected (SiHa and
HeLa) and non-infected cell lines (C33-A, a tumor cell line, and HaCaT, an immortalized keratinocyte cell line). Cell
surface expression of MICA was higher than cell surface expression of MICB in the HPV-positive cell lines; in
contrast, HPV-negative cells expressed lower levels of MICA. Interestingly, the MICA levels observed in C33-A cells
were overcome by significantly higher MICB expression. Also, all cell lines released higher amounts of soluble MICB
than of soluble MICA into the cell culture supernatant, although this was most pronounced in C33-A cells.
Additionally, Real-Time PCR analysis demonstrated that MICA was strongly upregulated after genotoxic stress.
Conclusions: This study provides evidence that even when MICA and MICB share a high degree of homology at
both genomic and protein levels, differential regulation of their expression and cell surface appearance might be
occurring in cervical cancer-derived cells.
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Background
The immune system endows vertebrates with the ability
to detect and respond to various challenges to the
homeostasis of the organism; among these, is the emer-
gence of nascent tumors. NK cells are major innate
effectors for the early recognition of transformed cells
because they can spontaneously detect their targets
without prior sensitization [1]. The killing activity is
mainly controlled by an exquisite balance of competing
inhibitory and activating receptors [2,3]. One of the best
characterized activating receptors is NKG2D, a C-type
lectin-like activating immunoreceptor whose expression
is confined to NK cells, CD8+ T cells and gδ T cells
[4,5]. More recently, the expression of NKG2D has been
described also in a small population of CD4+CD28- T
cells in patients with autoimmune conditions [6]. In
humans, NKG2D recognizes two structurally distinct
families of ligands named MHC class I chain-related
(MIC) molecules, and the UL16-binding proteins
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(ULBPs) 1 to 5, originally identified through interactions
with the cytomegalovirus UL16 glycoprotein. Both MIC
and ULBP proteins engage NKG2D, which then triggers
the cytokine production and cytotoxic activity seen in
activated NK cells [7-11].
It has been reported that MICA and MICB are weakly
expressed on healthy cells [12-14], but they can be up-
regulated by actively growing epithelial and hematologi-
cal tumors [15-20]. The molecular mechanisms involved
in the expression of MICA and MICB are still poorly
understood; however, experimental evidence has
revealed that their over-expression is the result of a
DNA damage response that involves the ATM (ataxia
telangiectasia mutated) and the ATR (ATM- and Rad3-
related) protein kinases [21,22]. Interestingly, it has been
demonstrated that the ATM/ATR pathway is crucial for
the regulation of the nuclear factor NF-B after the
induction of genotoxic stress [23] and NF-B has been
shown to be involved in the expression of MICA in T
cells [24]. Despite the fact that MICA and MICB share a
high homology at the DNA and protein level, there is
evidence for differential regulation of their promoters
[25] indicating that these molecules could respond dis-
similarly to several damage stimuli.
On the other hand, cervical cancer is one of the most
common malignant tumors in women worldwide,
[26,27]. Clinical, molecular and epidemiological data
have identified infection with human papillomavirus
(HPV) as a necessary cause for the development of this
tumor [28-31]. To date, over 100 different types of HPV
have been identified, and approximately 13 are consid-
ered as high-risk types with capability to transform cells
in the genital tract, with types 16, 18, 31, and 45 being
the most predominant types of HPV associated with
high-grade intraepithelial lesions and invasive cancer
[32-34]
This study was focused on gaining a better under-
standing of MICA and MICB expression at the molecu-
lar and cellular levels in human cervical cancer cell lines
infected or not with HPV and a non-tumorigenic kerati-
nocyte cell line. Our data provides evidence that despite
sharing a high degree of homology, MICA and MICB
might be differentially regulated at the transcriptional
and protein level. Therefore, it will be necessary to elu-
cidate if MICA and MICB acting together or individu-
ally are important participants in NKG2D-mediated
activation pathways in patients with HPV- associated
tumors.
Materials and methods
Cell lines and cell cultures
The human cervical cancer-derived cell lines (HeLa,
SiHa and C33-A) and the spontaneously immortalized
human epithelial cell line HaCaT (kindly obtained from
Dr. Boukamp, DKFZ-Heidelberg, Germany), which lacks
tumorigenic properties [35] were maintained in Dulbec-
co’s modified Eagle’s medium containing glutamax, 10%
fetal bovine serum, penicillin (100 U/mL) and strepto-
mycin (100 μg/mL). The aforementioned products were
obtained from GIBCO™ Invitrogen Corporation, Carls-
bad, CA, USA. Cultures were maintained at 37° C in a
humidified atmosphere with 5% CO2.
Etoposide treatment
Cultures of HaCaT and HeLa cells were treated with
etoposide (Laboratorios Lemery S.A. de C.V., México, D.
F.) at a concentration of 170 μM. Cells were incubated
at 37° C for 4 hours and used for RNA extraction.
MICA and MICB cell surface expression by flow cytometry
Surface MICA and MICB expression was evaluated by
flow cytometry. Briefly, cells from the different cultures
(HeLa, SiHa, C33-A and HaCaT) were harvested by
scraping and washed with PBS. Cells were adjusted at 8
× 105 cells/mL and incubated with primary mAb for 45
min at 4°C in the dark. Isotype controls were also
included. Finally, cells were analyzed using FACS Aria
(BD Biosciences). The following mouse mAbs were
used: PE-conjugated anti-MICA/B (clone 6D4, catalog
number sc-23868, Santa Cruz Biotech, Santa Cruz, CA,
USA), APC-conjugated anti-hMICA (clone 159227, cata-
log number FAB1300A, R & D Systems, Inc. Minneapo-
lis, MN, USA) and APC-conjugated anti-hMICB (clone
236511), catalog number FAB1599A, R & D Systems,
Inc. Minneapolis, MN, USA).
SDS-PAGE and Western blot analysis of MICA/B
Cells were harvested by scraping and then lysed with
RIPA buffer by sonication (10 pulses, 90% amp).
Extracts were incubated for 40 min at 4°C and
obtained by centrifugation (14000 rpm for 5 min at 4°
C). Protein concentration was determined using a pro-
tein quantitation kit (DC Protein Kit, BioRad, Hercules,
CA, USA) and 40 μg of whole-cell extract from each
cell type were analyzed by electrophoresis using a
12.5% SDS-PAGE. Proteins were then transferred to a
PVDF membrane (Millipore Corporation, Bedford,
MA, USA) and incubated with 5% w/v nonfat dry milk
to block nonspecific binding. Primary antibody anti-
MICA/B (clone F-6, Santa Cruz Biotech, Santa Cruz,
CA, USA) was incubated overnight at 4°C and second-
ary antibody was incubated with the membrane for 1 h
at RT, followed by chemiluminiscent detection (Milli-
pore Corporation, Bedford, MA, USA) using Kodak
BioMax Light films. MICA/B were visualized by the
presence of a band of approximately 62 kDa. The
images were obtained by computerized scanning of
films.
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Transcriptional expression of MICA and MICB by Real-
Time RT-PCR
Total RNA was isolated from cells with the PureLink™
Micro-to-Midi Total RNA Purification System (Invitro-
gen Corp., Carlsbad, CA, USA), as described by the
manufacturer. cDNA synthesis was performed using 5
μg of total RNA primed with oligo(dT) using the Super-
Script™ III First-Strand Synthesis System for RT-PCR
(Invitrogen Corp., Carlsbad, CA, USA). Real time PCR
analysis was performed using the LightCycler-FastStart
DNA MasterPLUS SYBR Green I Kit (Roche Applied
Science, Mannheim, Germany) using the LightCycler 1.5
System (Roche, Mannheim, Germany). In each assay,
standard curves with four serial dilution points of the
cDNA mixture and a negative control were included.
The relative quantification analysis for gene expression
was performed with the LightCycler Software v4 using
GAPDH, b-Actin and L32 ribosomal protein as refer-
ence genes. The oligonucleotides for MICA, MICB and
constitutive genes are described in Table 1.
Quantification of soluble MICA and soluble MICB in cell
culture supernatants by ELISA assay
MICA and MICB ELISA kits (catalog numbers DY1300
and DY1599, respectively both from R&D Systems, Inc.
Minneapolis, MN, USA) were used to detect soluble
MICA and soluble MICB in cell culture supernatants
(depleted of <10 kDa proteins) of HaCaT, C33-A, SiHa
and HeLa cell cultures, following the manufacturer’s
protocol. Absorbance values (at A450) by duplicate were
plotted against dilutions and expressed as pg/mL.
Ethical approval
This Protocol was approved by the Committees of
Research, Ethics & Biosafety with the registration num-
ber CI-4608 of the Centro Universitario de Ciencias de
la Salud - Universidad de Guadalajara and by the Ethical
Board CLIS-1305 of the Centro de Investigación
Biomédica de Occidente - IMSS with the registration
number R-2007-1305-1.
Results
Cell surface expression of MICA/B in cervical cancer-
derived cell lines and non-tumorigenic keratinocytes
There is evidence that overexpression of MICA/B
ligands, combined with other factors, is associated with
the survival and prognosis of cervical cancer patients
[36]. However, the role that HPV infection plays in the
regulation of MICA/B ligand expression still remains
unclear. In order to elucidate this point, we addressed
cell surface expression of MICA/B in various established
cervical tumor cell lines known to be infected with
HPV-18 (HeLa), HPV-16 (SiHa) or uninfected (C33-A).
Additionally, we included a human non-tumorigenic
immortalized cell line derived from epidermal keratino-
cytes (HaCaT), which has maintained the classical mor-
phological characteristics of differentiation comparable
with those of normal keratinocytes [35]. To assess
simultaneously the expression of MICA and MICB we
used a mAb that recognizes both molecules (clone 6D4).
As shown in Figure 1, a high percentage of MICA/B-
expressing cells with strong staining were observed in
the HPV infected SiHa and HeLa cell lines (83.4%/MFI
189.54 and 85.7%/MFI 116.71, respectively). Conversely,
only a low percentage of HPV-negative C33-A cells and
the non-tumorigenic HaCaT cells were weakly positive
for surface expression of MICA/B (25%/MFI 19.79 and
8.2%/MFI 3.82, respectively). Due to the fact that we did
not assess the expression of MICA/B ligands in primary
HPV-infected keratinocytes, we can not discard the pos-
sibility that HPV infection might be influencing the reg-
ulation of MICA/B cell surface expression.
MICA/B expression cell lysates from cervical cancer-
derived cell lines and non-tumorigenic keratinocytes
To determine whether the observed differences in cell
surface expression of MICA/B between HPV-positive
and -negative cell lines could be attributed to differences
in protein expression, we assessed their expression in
cell lysates by Western blot using a mAb. As shown in
Figure 2, in all cell lines this antibody recognized a band
of approximately 62 kDa, which corresponds with the
predicted MICA/B molecular weight. The analysis of the
signal of MICA/B in each cell line, after normalizing for
b-Actin, revealed that despite the lower surface expres-
sion observed on HaCaT and C33-A cells by flow cyto-
metry, these uninfected cells actually expressed
comparable amounts of total MICA/B protein. Interest-
ingly, while SiHa cells revealed a predominant band hea-
vier than 62 kDa, which could correspond to a higly
glycosylated form of MICA/B, C33-A cells showed a
lighter product, which could actually correspond to
Table 1 Oligonucleotides used in Real-Time RT-PCR
assays
Gene Oligonucleotides (5’- 3’)
MICA F CAG ACT GCC TGC AGG AAC TA
MICA R TTT CTT CTT ACA ACA ACG GAC ATA
MICB F CGG ACA GAC TTT CCA TAT GTT T
MICB R TCC AAC AAC AAT AAA TAA GTG ATG
b-Actin F TCC GCA AAG ACC TGT ACG
b-Actin R AAG AAA GGG TGT AAC GCA ACT A
GAPDH F CAC TGC CAC CCA GAA GAC TGT G
GAPDH R TGT AGG CCA TGA GGT CCA CCA C
RPL32 F GCA TTG ACA ACA GGG TTC GTA G
RPL32 R ATT TAA ACA GAA AAC GTG CAC A
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MICB, due to this molecule has five possible N-linked-
glycosylation sites (MICA has eight glycosylation sites).
However, we did not perform further experiments to
verify this finding.
Cell surface and soluble MICA and MICB expression
Next, we repeated our measurements of MICA/B on the
cell surface, this time using specific anti-MICA and
anti-MICB mAbs, which do not cross-react with each
other. Additionally, soluble MICA and MICB released
into the cell culture supernatants were also quantified.
As shown in Figure 3, nearly 100% of SiHa (HPV-16)
and HeLa (HPV-18) cells exhibited cell surface expres-
sion of MICA with median fluorescence intensities
(MFI) of 325.44 and 368.39, respectively. In contrast, the
HPV-negative cell lines C33-A and HaCaT cells showed
significantly lower values of MICA expression with
68.5% (MFI 26.59) and 49.7% (MFI 53.02) of positive
cells, respectively. For MICB, a higher percentage of
positive cells was detected in C33-A cells (94.6% MFI
84.6) than in HeLa (79.8%, MFI 40.06), SiHa (77.6%,
MFI 24.67) and HaCaT cells (33.9%, MFI 27.65). Inter-
estingly, the intensity of staining observed in C33-A
cells using the specific anti-MICB mAb was much stron-
ger than that observed with the antibody recognizing
MICA/B (clone 6D4), suggesting that the later antibody
might have a lower affinity for MICB. In summary,
these results show a significant expression of MICA
molecules on the cell surface of HPV-positive cell lines
compared to the HPV-negative cells. Conversely, our
data demonstrate that cell surface expression of MICB
was present in all the cell lines independently of the
HPV presence.
Interestingly, there is a discrepancy between the FACS
and Western blot experiments. We in fact expected to
find differences in the expression of MICA/B detected
by FACS and Western blot, since there are mechanisms
of shedding that regulate the availability of these ligands
at the cell surface. Additionally, there is evidence that
shedding (proteolytic) mechanisms can be modulated by
the presence of HPV. Thus, due to the observed shed-
ding of MICA and MICB from the cell surface, we
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Figure 1 MICA/B is differentially expressed in cervical cancer-derived cell lines. The cell surface expression of MICA/B was detected by flow
cytometry using an antibody that recognizes both MICA and MICB (open curves); IgG2a antibody isotype-control was also included (filled
curves). The histograms show the mean fluorescence intensity (MFI) and the percentage of MICA/B-expressing cells. Results were analyzed using
the program WinMDI.
Figure 2 MICA/B expression in total protein extracts from
cervical cancer-derived cell lines and non-tumorigenic
keratinocytes. Whole lysates from HaCaT, C33-A, SiHa and HeLa
cells were electrophoresed in SDS-PAGE gels under reductive
conditions and subjected to Western blot. A compact band of
approximately 62 kDa was visualized in almost all the cell lines. SiHa
instead revealed a band heavier than 62 kDa (b-Actin was used as
loading control).
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observed by Western blot will be “lost” to cell surface
FACS analysis.
Next, the release of soluble MICA and MICB into the
cell culture supernatants of subconfluent cultures of
HaCaT, C33-A, SiHa and HeLa cells was analyzed by
ELISA. As shown in Figure 4, all four-cell lines released
more soluble MICB than soluble MICA, and this effect
was more pronounced in C33-A cells, which exhibited
titers as high as 3830.65 pg/mL. This finding was similar
to the result obtained by flow cytometry, which had
revealed a high cell surface expression of MICB in C33-
A cells. On the other hand, the highest level of soluble
MICA was found in supernatant of HeLa cells, reaching
370.12 pg/mL. Taken together, these results point to a
preferential release of MICB by the four cell lines, with
the highest levels in HPV-negative cell lines.
Quantitative analysis of MICA and MICB mRNA
To address the possibility that the differences observed
in cell surface expression of MICA and MICB between
cell lines could be due to a different amount of mRNA,
we performed quantitative analysis of MICA and MICB
mRNAs by Real-Time RT-PCR using GAPDH, b-Actin
and the ribosomal L32 transcripts as reference genes.
MICA and MICB mRNA in HeLa, SiHa and C33-A
cells were normalized against those obtained with
HaCaT cells, since these cells were considered as non-
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Figure 3 Cell surface MICA and MICB expression in cervical cancer-derived cell lines and non-tumorigenic keratinocytes. Flow
cytometry analysis to detect MICA and MICB separately was carried out on HaCaT, C33-A, SiHa and HeLa cells to determine the percentage and
the mean fluorescence intensity of MICA and MICB. Results were analyzed using the program WinMDI (filled gray curves: isotype control, black
curves: anti-MICA, gray curves: anti-MICB).
Figure 4 Soluble MICA and MICB in supernatants from human cervical cancer cell lines and non-tumorigenic keratinocytes. Levels of
soluble MICA and soluble MICB were measured in concentrated supernatants of HaCaT, C33-A, SiHa and HeLa cells after three days of cell
culture by ELISA assays using the corresponding anti-MICA or anti-MICB monoclonal antibodies. Absorbance values (at A450) measured by
duplicate were plotted against standard dilutions and were expressed as pg/mL.
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5, C33-A, SiHa and HeLa cells exhibited higher relative
expression of MICA (1.79, 2.22 and 2, respectively)
when compared with MICA mRNA levels of HaCaT
cells (whose value was normalized to 1). For MICB, we
observed in C33-A cells (2.5 fold increase over the
HaCaT MICA standard), followed by SiHa (2.05 fold),
HeLa (1.83 fold) and HaCaT (1.39 fold). In contrast
with the other three cell lines, MICB mRNA abundance
was higher than MICA mRNA abundance in C33-A
(Figure 5). These data are consistent with the data
obtained by flow cytometry, where we observed a higher
expression of MICB than MICA (see Figure 3). Specific
amplification of MICA (amplicon of 448 bp) and MICB
(amplicon of 350 bp) were observed in 2% agarose gels
(Figure 5 shows the results obtained with HeLa cells).
Genotoxic stress induces preferential MICA expression
As we noted quantitative differences in the expression
levels of MICA and MICB genes, we speculated that
both genes might respond differentially to several sti-
muli, such as those induced by genotoxic stress. To
address this question, one HPV-negative and one HPV-
positive cell line (HaCaT and HeLa, respectively) were
treated with 170 μM etoposide for 4 h and MICA and
MICB mRNA abundance was assessed by Real-Time
PCR using GAPDH and b-Actin as reference genes.
After 4 h of treatment, we observed that genotoxic
stress caused increase in MICA mRNA in HeLa cells
(5.2-fold) and in HaCaT cells (68-fold) compared to
untreated cells (Figure 6). Conversely, MICB mRNA
increased only two-fold after etoposide treatment in
both cell lines (Figure 6). While not as striking as the
changes in MICA mRNA, levels of MICB mRNA
increased over two-fold after etoposide treatment (Fig-
ure 6). To follow up on this result we also measured
cell surface expression of MICA and MICB in HaCaT
and HeLa cells after etoposide treatment, but no signifi-
cant difference was observed (data not shown). A possi-
ble explanation for this discrepancy could be the short
time frame of the experiment (4 h). However, the quan-
titative differences observed in the mRNA levels of
MICA and MICB genes suggest that both genes might
respond differentially to damage stimuli.
Discussion
Since the discovery of “null” killer cells more than 30
years ago, there has been a large body of evidence
implying the participation of NK cells in the recognition
and lysis of tumor cells [37-39]. It is currently known
that the activity of NK cells is delicately controlled by a
balance between inhibitory and activating receptors [40].
NKG2D, one of the best characterized NK cell activating
receptors, can promote tumor lysis upon recognition of
MICA, MICB or the ULBPs. [41-43].
Figure 5 Relative quantification analysis of MICA and MICB genes. A) Relative expression of MICA and MICB in each cell line was performed
by Real-Time PCR using GAPDH, b-Actin and L32 ribosomal protein as reference genes. The “fold expression” (ordinates) was obtained by
normalizing the data values taking MICA expression of HaCaT cells as 1. The figure represents the average ± SD of the relative expression
obtained with the reference genes. B) Temperature melting analysis performed by Real-time RT-PCR shows amplification of only one specific
peak for each set of primers. C) Specificity of MICA and MICB amplification fragments was demonstrated by running the amplification products
on 1.5% agarose gel, giving a fragment of approximately 448 bp for MICA and 350 bp for MICB.
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Up-regulated expression of MICA/B on the tumor cell
surface has been considered a “danger signal” in order
to activate NKG2D-expressing cells and promote anti-
tumor immunity [4,13,42] However, numerous studies
have demonstrated tumor evasion through metallopro-
tease-induced proteolytic release of MICA and MICB
from the cell surface, which provokes down-regulation
of NKG2D in NK and T cells [44-47]. Recently, we
demonstrated increased soluble MICA levels in sera
from patients with cervical cancer and precursor lesions
as compared with healthy donors [48]. However, in that
study we did not test a correlation between soluble
MICA amounts and MICA expression in cervical tis-
sues. Therefore, in the present study we performed a
systematic analysis of the MICA and MICB expression
in human cervical cancer cell lines. The majority of
malignant cervical tumors are associated with infection
by HPV-16 and HPV-18 [49]. Therefore, we chose SiHa
and HeLa cells for our study, which are infected with
these virus types. We also included an HPV-negative
cervical cancer cell line (C33-A), as well as an HPV-
negative, spontaneously immortalized human keratino-
cyte cell line (HaCaT) with a highly preserved differen-
tiation capacity comparable to that of normal
keratinocytes [35]. In this study we used different clones
of antibodies against MICA/B (clone 6D4), MICA (clone
159227) and MICB (clone 236511). Interestingly, we
observed starkly different MFI with the different antibo-
dies. Of particular interest is the difference between the
MICA/B MFI spread between SiHa and HeLa
(189.54:116.71) that is not at all seen in the MICA stain-
ing of those cells, which were essentially identical
(325.44:368.39). From this, we conclude that the com-
mon anti-MICA/B antibody must be binding different
epitopes with different affinities than the individual anti-
bodies. It is tempting to imagine that the individual
MICA antibody binds an epitope that is conserved
between HeLa and SiHa cells, while the MICA/B anti-
body binds an epitope that might be slightly different
between the two cell lines, leading to different binding
affinities. Our data on the preferential cell surface
expression of MICA over MICB in SiHa cells are in
agreement with a recent study examining activating NK
ligands in various cell lines (including SiHa) and in
tumor cells from patients with cervical cancer [50].
Due to the fact that the tumor cell lines tested in our
study showed a significant cell surface expression of
MIC molecules, the question is still open as to whether
or not these tumor cells are able to escape from the
normally efficient NK cell activation through the MIC/
NKG2D pathway. For instance, sustained expression of
NKG2D ligands has been shown to promote downregu-
lation of the NK cell functions in transgenic mice con-
stitutively expressing Rae-1ε [51]. One mechanism by
which the persistent MIC ligand expression could affect
NK cell activity is by shedding MIC molecules from the
tumor cell surface. In other words, the constitutive MIC
expression on the tumor cell surface might be a contin-
uous source of soluble MIC molecules, which are
thought to engage the NKG2D receptor and cause its
internalization and subsequent lysosomal degradation
[47]. The high levels of soluble MICB found in the pre-
sent study suggest that this ligand might play a different
biological role than MICA. In support of this is the fact
that elevated soluble MICB correlated with disease activ-
ity in patients with multiple sclerosis during relapses
while soluble MICA did not show any association with
the disease; rather, the levels of this ligand were similar
to healthy controls [52]. Therefore, an issue of vital
importance will be to address if both soluble MICA and
MICB share the same biological function in patients
with HPV-associated tumors and to determine whether
MICB, which was found in a higher concentration than
MICA in the supernatants of cervical cancer cell lines,
could promote NKG2D downmodulation in NK cells of
cervical cancer patients. It will be also interesting to
investigate if MICA and MICB show different mechan-
isms of posttranslational control; for instance, Agüera-
González et al., showed recently that MICB has a short
time of residence at the plasma membrane and
Figure 6 Relative quantification analysis of the expression
levels of MICA and MICB genes after etoposide-induced stress.
We treated HaCaT and HeLa cells with 170 μM etoposide during 4
h. After RNA extraction and retrotranscription, Real-Time PCR was
performed using GAPDH and b-Actin as reference genes. The “fold
expression” (ordinates) was obtained by normalizing the data values
with the untreated cells, which was arbitrarily set at 1. The figure
represents the average ± SD of the relative expression obtained
with the reference genes.
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demonstrated that MICB shedding was one of the
mechanisms that contributes to the rapid loss of ligand
from the cell surface [53]. Thus, if high levels of soluble
MICB are present in the serum of cervical cancer
patients, and this contributes to tumor immune escape,
targeting of this molecule could be a promising alterna-
tive to improve tumor immunosurveillance in these
patients.
The Real-Time RT-PCR results for MICB are espe-
cially interesting in light of the flow cytometry and
ELISA data. While MICB transcripts were slightly lower
than those for MICA in the HPV-positive cell lines,
C33-A cells showed the opposite. The same finding
could be observed by cell surface staining (with apparent
MFIs of 84.60 versus 24.67 and 40.06 for SiHa and
HeLa, respectively) and also in the ELISA experiments
for soluble MICB in the culture supernatant. Despite
the fact that MICB appears to be less polymorphic than
MICA, polymorphisms in the MICB promoter, with
important variations in transcription rates, have been
described [54]. If this is the case here, then these poly-
morphisms might partly explain the higher transcrip-
tional rate that we observed in the C33-A cell line.
More importantly, the results with etoposide demon-
strated that while MICB mRNA level rose slightly after
treatment, MICA mRNA was strikingly upregulated,
especially in non-tumorigenic HaCaT cells (68-fold
increase). To follow up on this result, we also measured
cell surface expression of MICA and MICB in HaCaT
and HeLa cells after 4 h of etoposide treatment, but no
significant difference was observed (data not shown). A
possible explanation for this discrepancy might be the
short time frame of the experiment. However, the quan-
titative differences observed in the mRNA levels of
MICA and MICB genes in response to etoposide treat-
ment suggest that both genes could be regulated in dif-
ferent ways. Indeed, a recent study that analyzed the
architecture and function of the promoter of the MIC
genes provided evidence for differential regulation of
MICA and MICB [25].
Taken together, our results suggest that in spite of
sharing a high degree of homology at both genomic and
structural levels, MICA and MICB are differentially
regulated at the transcriptional level and by cleavage at
the cell surface in response to varying danger signals.
Additionally, our data might point to roles for both
ligands in the escape from immunosurveillance by
tumor cells: sustained over-expression of MICA at the
cell surface of HPV-positive cells, which could promote
downregulation of the NK cell functions; and the shed-
ding of MICB in HPV-negative cervical cancer cells,
which could bind to NKG2D receptors and outcompete
cell-surface activating ligands. Modulating the cell sur-
face expression or targeting the proteases that mediate
shedding of NKG2D ligands may open a new approach
for the treatment of cervical cancer.
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